Atyr PHARMA (NASDAQ:ATYR) Upgraded by Leerink Partnrs to “Strong-Buy” Rating

Atyr PHARMA (NASDAQ:ATYR) was upgraded by research analysts at Leerink Partnrs to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

A number of other research analysts have also commented on ATYR. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Leerink Partners assumed coverage on Atyr PHARMA in a research note on Tuesday. They set an “outperform” rating and a $16.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on Atyr PHARMA in a research note on Monday, January 6th. They set an “overweight” rating for the company. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Stock Performance

Shares of NASDAQ ATYR opened at $3.79 on Tuesday. The business has a fifty day simple moving average of $3.55 and a 200 day simple moving average of $2.83. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $318.13 million, a price-to-earnings ratio of -4.03 and a beta of 1.10. Atyr PHARMA has a one year low of $1.42 and a one year high of $4.22.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its stake in Atyr PHARMA by 52.0% during the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock worth $55,000 after acquiring an additional 10,754 shares in the last quarter. Alterna Wealth Management Inc. bought a new stake in shares of Atyr PHARMA during the fourth quarter worth $36,000. Kingswood Wealth Advisors LLC bought a new stake in shares of Atyr PHARMA during the fourth quarter worth $170,000. American Century Companies Inc. bought a new stake in shares of Atyr PHARMA during the fourth quarter worth $319,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Atyr PHARMA during the fourth quarter worth $39,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.